LinKinVax and Gustave Roussy collaborate to conduct a Phase I/IIa HPV.DCVax clinical trial for the treatment of patients with human papillomavirus (HPV) associated oropharyngeal cancer
Accelerating the production of more effective prophylactic or therapeutic vaccines and adapting them to emerging or rapidly mutating pathogens is a major public health challenge.
LinKinVax puts together a highly experienced team from the world of biopharmaceuticals to lead the clinical development and upscaling of its vaccine platform
